Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alefacept for GVHD Prevention in SCT
NCT00361413Phase 3Terminated
- Sponsor
- Hadassah Medical Organization
- Start
- Jun 2006
- Primary completion
- Jul 2013
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in graft-versus-host disease (GVHD) comparing Alefacept Arm with Placebo Arm (2 arms). Primary endpoints: Acute Graft Versus Host Disease occurrence at 100 days and Acute Graft Versus Host Disease grading at 100 days. Started Jun 2006; status: terminated.
02
Drugs
alefacept
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00361413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00361413.